CCI Approves TPG Scion’s Acquisition of Schott Poonawalla Stake

06 Mar 2025 CW Team

TPG Scion SG Pte. Ltd. is a newly established special-purpose investment vehicle incorporated in Singapore on 11th October 2024, specifically for this transaction. Currently, it has no operational presence in India. It is affiliated with the TPG Group, a global, diversified investment firm founded in 1992. The TPG Group, which operates across multiple asset classes including private equity, real estate, and infrastructure, manages investments worldwide. The transaction is ultimately controlled by an entity advised by affiliates of TPG Inc., the ultimate holding company of the group.

Schott Poonawalla Private Limited (SPPL), the target company, is engaged in the development, manufacturing, and sale of pharmaceutical packaging solutions. Its product portfolio includes sterile and non-sterile glass containers such as ampoules, vials, cartridges, and prefilled syringes, which are critical components for the pharmaceutical and biotechnology industries. The company specialises in converting tubular glass into primary packaging solutions, ensuring high standards of safety and integrity for pharmaceutical formulations.

Strategic Importance of the Acquisition The acquisition aligns with TPG’s strategy of investing in high-growth sectors, particularly healthcare and life sciences. With India being a global leader in pharmaceutical manufacturing, the demand for high-quality primary packaging solutions has surged, driven by the rise in vaccine production, biologics, and injectable therapies.

The CCI’s approval paves the way for enhanced investments, technological advancements, and global expertise infusion in India's pharmaceutical packaging segment. The partnership between TPG and SPPL is expected to strengthen supply chain efficiencies, improve manufacturing capabilities, and support innovation in sterile and injectable packaging solutions.

Market and Industry Outlook India’s pharmaceutical packaging market is witnessing robust growth, propelled by increasing regulatory requirements, demand for biologics, and the rise of single-dose drug delivery systems. The expansion of vaccine production and the growth of biosimilars and novel therapies have amplified the need for advanced packaging solutions.

With global investors such as TPG entering the segment, the industry is poised for enhanced technological collaborations, automation in manufacturing, and sustainable packaging innovations. The acquisition of a stake in Schott Poonawalla Private Limited is expected to strengthen India’s position as a global hub for pharmaceutical packaging, ensuring compliance with stringent international standards while catering to the evolving needs of the pharmaceutical industry.

"Join industry leaders at RAHSTA Expo, India's premier platform for roads, highways and traffic infrastructure. Register now to explore innovations, network with experts and shape the future of mobility."

The Competition Commission of India (CCI) has approved the proposed acquisition of a stake in Schott Poonawalla Private Limited (SPPL) by TPG Scion SG Pte. Ltd., marking a significant development in the pharmaceutical packaging sector. The acquisition will be executed through a secondary share purchase from Serum Institute of India Private Limited. TPG Scion SG Pte. Ltd. is a newly established special-purpose investment vehicle incorporated in Singapore on 11th October 2024, specifically for this transaction. Currently, it has no operational presence in India. It is affiliated with the TPG Group, a global, diversified investment firm founded in 1992. The TPG Group, which operates across multiple asset classes including private equity, real estate, and infrastructure, manages investments worldwide. The transaction is ultimately controlled by an entity advised by affiliates of TPG Inc., the ultimate holding company of the group. Schott Poonawalla Private Limited (SPPL), the target company, is engaged in the development, manufacturing, and sale of pharmaceutical packaging solutions. Its product portfolio includes sterile and non-sterile glass containers such as ampoules, vials, cartridges, and prefilled syringes, which are critical components for the pharmaceutical and biotechnology industries. The company specialises in converting tubular glass into primary packaging solutions, ensuring high standards of safety and integrity for pharmaceutical formulations. Strategic Importance of the Acquisition The acquisition aligns with TPG’s strategy of investing in high-growth sectors, particularly healthcare and life sciences. With India being a global leader in pharmaceutical manufacturing, the demand for high-quality primary packaging solutions has surged, driven by the rise in vaccine production, biologics, and injectable therapies. The CCI’s approval paves the way for enhanced investments, technological advancements, and global expertise infusion in India's pharmaceutical packaging segment. The partnership between TPG and SPPL is expected to strengthen supply chain efficiencies, improve manufacturing capabilities, and support innovation in sterile and injectable packaging solutions. Market and Industry Outlook India’s pharmaceutical packaging market is witnessing robust growth, propelled by increasing regulatory requirements, demand for biologics, and the rise of single-dose drug delivery systems. The expansion of vaccine production and the growth of biosimilars and novel therapies have amplified the need for advanced packaging solutions. With global investors such as TPG entering the segment, the industry is poised for enhanced technological collaborations, automation in manufacturing, and sustainable packaging innovations. The acquisition of a stake in Schott Poonawalla Private Limited is expected to strengthen India’s position as a global hub for pharmaceutical packaging, ensuring compliance with stringent international standards while catering to the evolving needs of the pharmaceutical industry.

Real Estate

07 Jul 2026

Pecan Realty Completes Rs 1.5 Billion Transactions

Pecan Realty has recently completed four institutional transactions worth over Rs 1.5 billion over the past two years, strengthening its position as an execution-led real estate platform. The deals include resolution-led acquisitions, structured finance transactions and capital partnerships across its development portfolio.The transactions covered acquisitions through the National Company Law Tribunal process and helped provide repayment or exits to both private and public sector lenders. The company said the deals demonstrate its ability to resolve complex project situations, work with instit..

Real Estate

07 Jul 2026

SNN Estates Expands North Bengaluru Housing Project

SNN Estates has announced an expansion of its SNN Estates Felicity residential project in North Bengaluru following strong buyer demand, with 75 per cent of the first-phase inventory sold within three days of launch.The developer will add 76 apartments in the new phase, taking the project's estimated revenue potential to around Rs 1,000 crore upon completion of Phase 2.Spread across 6.5 acres in Rachenahalli, near Manyata Tech Park, the project comprises 604 apartments in 1.5, 2, 2.5, 3 and 4 BHK configurations. The development includes a 50,000-sq-ft clubhouse with amenities such as sports co..

Infrastructure Urban

07 Jul 2026

SCG Drives ASEAN Industrial Transformation Strategy

SCG is strengthening its focus on ASEAN as a key growth region by advancing industrial transformation, enhancing competitiveness and building resilient regional value chains. Thammasak Sethaudom, President and Chief Executive Officer, SCG, highlighted the need for industries to continuously develop capabilities, strengthen resilience and deepen regional cooperation to achieve sustainable long-term growth.SCG views ASEAN as an important growth engine alongside China, supported by favourable demographics, trade connectivity and investment flows. With ASEAN’s GDP projected to grow by around 4.7..